LIASTEN is prescribed as an immunomodulatory agent for various diseases accompanied by secondary immunodeficiency, leukopenia, in particular, for chemo-and radiation therapy of cancer patients and patients with leukemia in order to reduce the toxic effect of cytostatics; for acute and chronic radiation injuries; for surgical treatment of cancer patients and other categories of patients.
active substance: 1 tablet contains 2 mg of glucosaminylmuramylpentapeptide in terms of peptides;
excipients: hypromellose (hydroxypropyl methylcellulose) lactose monohydrate, magnesium stearate, croscarmellose sodium; sorbitol (D-sorbitol) (E 420) microcrystalline cellulose.
Liasten Dosage form
Basic physical and chemical properties: tablets of white or light yellow color, flat-cylindrical, without a shell with a line.
Liasten Pharmacotherapeutic group
Immunostimulants. ATX code L03A X.
Liasten Pharmacological properties
LIASTEN® belongs to immunomodulators of natural origin with a wide spectrum of action. It is a fragment of the cell wall of lactobacilli. LIASTEN® stimulates the function of macrophages and normalizes the number of T-lymphocytes; activates cells of the monocytic-macrophage series, phagocytosis, increases the activity of lysosomal enzymes, production of reactive oxygen species, enhances the cytotoxic effect of macrophages in relation to cells infected with viruses, bacteria and tumor cells. The drug enhances the synthesis of pro-inflammatory cytokines, in particular interleukin-1; increases the cytotoxic activity of natural killer cells. The immunomodulatory activity of LIASTEN® is also manifested in the fact that the drug preserves the endocrine function of the thymus, helps to reduce the level of circulating immune complexes. LIASTEN® promotes the stimulation of leukopoiesis, has a weak antimetastatic and antitumor effect, reduces the severity of side effects of chemotherapy and radiation therapy. The drug has no embryotoxic, mutagenic and teratogenic effects.
LIASTEN® is prescribed as an immunomodulatory agent for various diseases accompanied by secondary immunodeficiency, leukopenia, in particular during chemotherapy and radiation therapy of cancer patients and patients with leukemia in order to reduce the toxic effect of cytostatics; with acute and chronic radiation injuries; in the surgical treatment of cancer patients and other categories of patients. LIASTEN® is indicated for acute and chronic bacterial and viral infections, in particular for tuberculosis, as well as for the treatment of patients with leukopenia of various origins.
Hypersensitivity to the components of the drug, autoimmune thyroiditis in the acute phase; conditions in diseases accompanied by hyperthermia (> 38 ° C) at the time of taking the drug.
Interaction with other medicinal products and other types of interactions
Patients with rare hereditary diseases such as galactose intolerance, Lapp lactase deficiency or impaired glucose-galactose malabsorption should not take this drug.
If you have a history of intolerance to some sugars, consult your doctor before taking this medication, as this medication contains D-sorbitol and lactose monohydrate.
The ability to influence the reaction rate when driving or operating machinery
The drug does not affect the reaction rate when driving or using other mechanisms.
Use during pregnancy or lactation
There is no experience of using the drug for pregnant and lactating women.
Method of administration and dosage
Liasten® tablets are intended for slow absorption in the oral cavity. It is advisable to slowly dissolve the tablet under the tongue. Usually, 1 tablet is prescribed 2 times a day. The course of treatment is usually 10 to 20 days. If necessary, you can carry out repeated courses of treatment after 3 – 6 and 12 months.
There is no experience of using the drug in children.
It is practically excluded, since the minimum toxic doses exceed the therapeutic ones by 650 times.
Sometimes a short-term slight increase in body temperature is possible, does not require discontinuation of the drug and special medical measures, hypersensitivity reactions.
Store at a temperature not exceeding 25 ° C. Out of the reach of children.
There are 10 tablets in a blister, 2 blisters in a cardboard box.